Table 1.
Engraftment of AML cell subpopulations in NSG mice
| a. ALDH‐rare AML | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD34+ALDH+ | CD34‐ALDH+ | CD34+CD38‐ALDH‐ | Rest of ALDH‐ | |||||||
| AML no. | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis | Dose (×103) | Engrafted/total mice (% human CD45+ cells) |
| AML BM67 | 1 | 0/2 | 0.4 | 0/1 | 5–50 | 0/3 | 50–1,000 | 0/4 | ||
| 4.5 | 1/2 (0.03%) | Normal | 150 | 1/1 (21.85%) | AML | |||||
| AML BM72 | 4 | 2/2 (0.07%) | Normal | 5–20 | 0/2 | 5–140 | 0/3 | 50–1,000 | 0/3 | |
| CD34+CD38−ALDH+ | CD34+CD38−ALDH‐ | |||||
|---|---|---|---|---|---|---|
| AML no. | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis |
| AML BM88 | 1 | 1/3 (0.05%) | Normal | 50 | 0/3 | |
| AML BM134 | 1,4 | 1/3 (0.14%) | Normal | 11,4 | 0/4 | |
| AML BM93 | 1,7 | 1/3 (0.02%) | Normal | 145 | 0/3 | |
| b. ALDH‐numerous AML | ||||||
|---|---|---|---|---|---|---|
| CD34+ALDH+ | CD34+ALDH‐ | |||||
| AML no. | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis | Dose (×103) | Engrafted/total mice (% human CD45+ cells) | AML/normal hematopoiesis |
| AML BM42 | 5 | 0/1 | 50 | 0/1 | ||
| 50 | 1/1 (5.86%) | AML | 125 | 0/1 | ||
| 125 | 1/1 (3.39%) | AML | 1,000 | 1/1 (3.55%) | AML | |
| AML BM80 | 50 | 1/1 (67.65%) | AML | NA | ||
| 210 | 2/2 (70.13%) | AML | 210 | 2/2 (63.58%) | AML | |
| 1,000 | 1/1 (68.15%) | AML | NA | |||
| AML BM78 | 350 | 1/2 (0.13%) | AML | 426 | 0/1 | |
| 677 | 1/1 (0.06%) | AML | 750 | 0/1 | ||
| AML BM36 | 5–50 | 0/3 | 5–42 | 0/2 | ||
| AML BM76 | 50–248 | 0/3 | 62 | 0/1 | ||
Percentages or mean percentages of human CD45+ cells in xenografts are indicated. NA: not analyzed.